Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, we have developed an expertise in chromatography. Our products are used to purify pharmaceuticals during production using a technique called preparative chromatography.
We operate in a global niche market that is growing as a result of an increased demand for drugs for treating diabetes and obesity. Our silica-based purification media for preparative chromatography, NLAB Saga®, has been especially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for NLAB Saga®, it can increase productivity and reduce costs for pharmaceutical manufacturers.
Our mission is to increase access to cost-effective drugs through its purification products, and thereby enable more patients around the world access to life-saving treatments for diabetes and obesity.
By developing chromatography products that enable pharmaceutical manufacturers to streamline production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access to adequate treatments.
The nomination committee of Nanologica proposes to the Annual General Meeting on May 21 that Mark Quick and Erik Haeffler
Nanologica AB (publ) (”Nanologica” or ”the Company”) hereby announces the outcome of the two directed issues of shares resolved by
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
FINANCIAL SUMMARY Net sales for the fourth quarter amounted to SEK 5,205 thousand (6,715) and for the full year to
FINANSIELL SAMMANFATTNING Nettoomsättningen för fjärde kvartalet uppgick till 5 205 TSEK (6 715) och för helåret till 21 127 TSEK (14
FINANCIAL SUMMARY Net sales for the third quarter amounted to SEK 2,843 thousand (611) and for the nine-month period to
After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized by both increasing volumes and an increased focus on costs.
Follow this link for more video presentations and CEO interviews.
Company presentation made by CEO Andreas Bhagwani in September 2025.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
For further information, please contact:
Johanna Johansson
Director IR, Communications and Marketing
